Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 in HER2+ non-small cell lung cancer
NCT06496490Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in non-small cell lung cancer (NSCLC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Aug 2024; status: recruiting.
02
Drugs
TQB2102
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06496490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496490.